Skip to main content
Fig. 2 | Virology Journal

Fig. 2

From: Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells

Fig. 2

Time-dependent effect of IL-17A pretreatment on the anti-HBV activity of IFN-α. HepG2-HBV1.3 cells were pretreated with or without 50 ng/ml IL-17A for indicated time (6, 12, 24, or 48 h), followed by co-treatment with or without 1000 IU/ml IFN-α for 48 h. A Culture supernatants were collected for assay of levels of HBsAg, HBeAg or HBV DNA. Data were displayed as a percentage of the values obtained for mock-treated cells. B Cell lysates were prepared for HBs and HBc protein by western blotting. Relative expression of protein was shown as fold-change in comparison with the mock-treated cells. All data were shown as mean ± standard deviation (SD) (error bars) from at least 3 independent experiments. p < 0.05 is considered statistically significant. *p < 0.05, **p < 0.01 between two indicated groups

Back to article page

Virology Journal

ISSN: 1743-422X